Cargando…

Channelopathy of Dravet Syndrome and Potential Neuroprotective Effects of Cannabidiol

Dravet syndrome (DS) is a channelopathy, neurodevelopmental, epileptic encephalopathy characterized by seizures, developmental delay, and cognitive impairment that includes susceptibility to thermally induced seizures, spontaneous seizures, ataxia, circadian rhythm and sleep disorders, autistic-like...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Changqing, Zhang, Yumin, Gozal, David, Carney, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724990/ https://www.ncbi.nlm.nih.gov/pubmed/34992485 http://dx.doi.org/10.1177/11795735211048045

Ejemplares similares

Channelopathy as a SUDEP Biomarker in Dravet Syndrome Patient-Derived Cardiac Myocytes
por: Frasier, Chad R., et al.
Publicado: (2018)

Cannabidiol for epilepsy (Lennox-Gastaut syndrome, Dravet syndrome)
Publicado: (2020)

Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea
por: Koo, Chung Mo, et al.
Publicado: (2020)

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
por: Devinsky, Orrin, et al.
Publicado: (2018)

Cannabidiol improves survival and behavioural co‐morbidities of Dravet syndrome in mice
por: Patra, Pabitra Hriday, et al.
Publicado: (2020)

Dravet syndrome
por: Incorpora, Gemma
Publicado: (2009)

A review of fenfluramine for the treatment of Dravet syndrome patients
por: Simon, Kayla, et al.
Publicado: (2021)

Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex
por: Silvinato, Antônio, et al.
Publicado: (2022)

Combined Antiseizure Efficacy of Cannabidiol and Clonazepam in a Conditional Mouse Model of Dravet Syndrome
por: Chuang, Shu-Hui, et al.
Publicado: (2021)

Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial
por: Devinsky, Orrin, et al.
Publicado: (2018)

Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials
por: Madan Cohen, Jennifer, et al.
Publicado: (2021)

Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox–Gastaut Syndrome
por: Lattanzi, Simona, et al.
Publicado: (2021)

Caregivers’ Perspectives on the Impact of Cannabidiol (CBD) Treatment for Dravet and Lennox-Gastaut Syndromes: A Multinational Qualitative Study
por: Marshall, Jade, et al.
Publicado: (2023)

Channelopathies
por: Kim, June-Bum
Publicado: (2014)

Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox–Gastaut Syndrome
por: Iannone, Luigi Francesco, et al.
Publicado: (2021)

Vaccinations and Dravet Syndrome
por: Korff, Christian M.
Publicado: (2015)

Phenotypes of Dravet Syndrome
por: Garcia-Sosa, Rebecca, et al.
Publicado: (2016)

Dravet Syndrome: An Overview
por: Anwar, Arsalan, et al.
Publicado: (2019)

Stiripentol for Dravet syndrome
Publicado: (2020)

Cannabidiol's neuroprotective properties and potential treatment of traumatic brain injuries
por: Aychman, Mackenzie M., et al.
Publicado: (2023)

Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial
por: Miller, Ian, et al.
Publicado: (2020)

Channelopathies – An update 2018
por: Natarajan, K.U., et al.
Publicado: (2019)

Brugada Syndrome: More than a Monogenic Channelopathy
por: Liantonio, Antonella, et al.
Publicado: (2023)

Crouch Gait in Dravet Syndrome
por: Black, Laura, et al.
Publicado: (2016)

Anesthetic considerations in Dravet syndrome
por: Macdonald‐Laurs, Emma, et al.
Publicado: (2022)

Epilepsy in Dravet Syndrome—Current and Future Therapeutic Opportunities
por: Gao, Chao, et al.
Publicado: (2023)

Cardiac Ion Channelopathies and the Sudden Infant Death Syndrome
por: Wilders, Ronald
Publicado: (2012)

Dravet Syndrome as an Example of Precision Medicine in Epilepsy
por: Sullivan, Joseph, et al.
Publicado: (2022)

Potassium Channelopathies and Gastrointestinal Ulceration
por: Han, Jaeyong, et al.
Publicado: (2016)

KCNMA1-linked channelopathy
por: Bailey, Cole S., et al.
Publicado: (2019)

Do All Roads Lead to Rome? Genes Causing Dravet Syndrome and Dravet Syndrome-Like Phenotypes
por: Ding, Jiangwei, et al.
Publicado: (2022)

Concealed Substrates in Brugada Syndrome: Isolated Channelopathy or Associated Cardiomyopathy?
por: Di Resta, Chiara, et al.
Publicado: (2022)

Fatal Status Epilepticus in Dravet Syndrome
por: De Liso, Paola, et al.
Publicado: (2020)

Atrial fibrillation in Cardiac Channelopathies
por: Thejus, Jayachandran, et al.
Publicado: (2009)

Muscle channelopathies and electrophysiological approach
por: Cherian, Ajith, et al.
Publicado: (2008)

Inherited arrhythmias: The cardiac channelopathies
por: Behere, Shashank P, et al.
Publicado: (2015)

On the Right Trk: Towards an Effective Treatment for Dravet Syndrome
por: Wong, Jennifer C.
Publicado: (2022)

Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease
por: Giuliano, Claudio, et al.
Publicado: (2021)

Chloride Channelopathies of ClC-2
por: Bi, Miao Miao, et al.
Publicado: (2013)

Ion Transporters, Channelopathies, and Glucose Disorders
por: Demirbilek, Huseyin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_05cgfp2vr6nhohv8mausa8k2gj